NRF2 THROUGH RPS6 ACTIVATION IS RELATED TO ANTI-HER2 DRUG RESISTANCE IN HER2-AMPLIFIED GASTRIC CANCER.
Despite the clinical advantage of the combination of trastuzumab and platinum-based chemotherapy in HER2-amplified tumors, resistance will eventually develop. The identification of molecular mechanisms related to primary and acquired resistance is needed. We generated lapatinib- and trastuzumab-resistant clones deriving from two different HER2-amplified gastric cancer cell lines. Molecular changes such as protein expression and gene-expression […]
